FDA approves new oral drug to relieve constipation from opioid painkillers

Share this article:
Long-term care residents who experience constipation from taking opioids to manage chronic pain may benefit from Amitiza, an oral drug recently approved by the Food and Drug Administration.

Amitiza (lubiprostone) has already been approved in the United States for other conditions, such as constipation-related irritable bowel syndrome. Manufactured by Sucampo Pharmaceuticals Inc./Takeda Pharmaceuticals USA Inc., it is the first oral drug to relieve constipation caused by opioid therapy for managing noncancer pain.

Constipation is a common side effect for people who take oxycodone, fentanyl or other opioids on a long-term basis. Amitiza was approved by the FDA based on 12-week studies of people on these painkillers.

The drug's effectiveness when taken with diphenylheptane opioids, such as methadone, has not been established, according to the manufacturer. The company also warned that lubiprostone should not be taken by anyone with impaired liver function.

Share this article:

More in News

Antipsychotics reduction goal is 25% by end of 2015, CMS and provider groups announce

Antipsychotics reduction goal is 25% by end of ...

Long-term care providers are being asked to reduce the use of antipsychotic medications among residents by 25% by the end of 2015, and 30% by the end of 2016. Providers ...

CDC issues new guidelines on pneumococcal vaccine, says LTC flu vaccination rates remain low

CDC issues new guidelines on pneumococcal vaccine, says ...

Long-term care workers continued to have low rates of flu vaccination last season, despite there being 92% vaccination coverage overall among physicians and nurses, the Centers for Disease Control and ...

AL operators accused of withholding $2M in unpaid overtime, minimum wages ...

Four California assisted living operators are facing eight felony charges related to wage theft, tax and insurance violations, according to local reports.